Search
News & Events
Continuing the cancer fightWork by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.
News & Events
Apache Energy joins Telethon Institute in cancer research partnershipApache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership
News & Events
New study examines vacccine to prevent cervical cancerThe Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).
Research
Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemiaPre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms.
Research
Challenges posed by COVID-19 to children with cancerDevelopment of standardised guidance by national and regional authorities for reducing the risk of SARS-CoV-2 transmission to children with cancer
Research
Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemiaIt is now well accepted that germline or de novo genetic alterations predispose to cancer development, especially during childhood. Among them, constitutive trisomy 21, also known as Down syndrome (DS), has been shown to predispose to acute leukemia affecting both the myeloid (ML-DS) and lymphoid (DS-ALL) lineages. ML-DS is associated with a good prognosis compared to children without DS, due in part to a higher sensitivity to conventional chemotherapy.
Research
High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to LarotrectinibETV6::RUNX1 is one of the most common recurrent genomic abnormalities in acute lymphoblastic leukaemia (ALL) and is associated with a good prognosis. High expression of NTRK1, encoding tropomyosin receptor kinase A (TrkA), confers a poor prognosis in other malignancies and may contribute to therapy resistance in patients with ETV6::RUNX1 B-ALL.
Research
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemiaBiological changes associated with T-ALL relapse and resistance are stochastic and highly individual
Research
Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)Our findings support the hypothesis of a familial susceptibility of childhood brain tumors, not due to being a known neurofibromatosis carrier
Research
Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine modelsThis JAK3A572V knockin model is a relevant new tool for testing the efficacy of JAK inhibitors in JAK3-related hematopoietic malignancies